Life-threatening complications that require surgery during TAVR are infrequent. The proportion was originally thought to be between 1% and 2%. However, we now know that it is lower, even though we do not know how frequent it is or what are its most common causes. Its evolution, both in the short and in the long...
The association between aortic stenosis and coronary disease is common, since both conditions share pathogenesis, risk factors, and symptoms. Transcatheter aortic valve replacement (TAVR) is currently indicated for high-risk and inoperable patients. It also appears as a valid alternative for the treatment of intermediate-risk patients, and it could soon be indicated for low-risk patients. Coronary...
Courtesy of Dr. Carlos Fava. Even though the presence of paravalvular regurgitation (PVR) has been reduced, thank to greater experience and new devices, it is still frequent and has an impact in survival (especially moderate and severe PVR). Recent research has shown that mild PVR also has a negative impact. However, these data were provided...
Courtesy of Dr. Carlos Fava. Currently, some small observational studies and a meta-analysis suggest that women experience more short-term complications after TAVR (due to higher rates of bleeding, vascular complications, and stroke), as well as less 1-year mortality. However, results are still conflicting. This work analyzed 17 studies including 8 different registries, with a total 23,303 women and 23,885 men....
Courtesy of Dr. Carlos Fava. In most randomized or observational studies, women comprise more than 50% of patients undergoing TAVR, and they have showed better evolution, compared against surgery. The main differences between men and women with severe aortic stenosis are that women have smaller annular dimension, shorter distance to coronary ostia, smaller peripheral arteries, and...
Courtesy of Dr. Carlos Fava. Peripheral vascular diseases (PVD) present the same risk factors as aortic stenosis. In consequence, these disorders usually coexist. The frequency and impact of their various stages on patients undergoing TAVR is yet to be thoroughly assessed. Read also: “Peripheral Vascular Disease Is Associated to More Events in TAVR”. This study analyzed...
Durability: Evidence on TAVR and Long-Term Outcomes. Presenters: Dr. Diego Godoy, Chile. Dr. Juan Gaspar, Uruguay. This video, sponsored and funded by Medtronic, was filmed during SOLACI-CACI 2017 Congress, at Hilton Buenos Aires Hotel (in Argentina). Do you want to take a look at all other SOLACI-CACI 2017 Congress Medtronic cases? Watch them We are interested in your opinion....
Percutaneous Interventions After TAVR. Presenters: Dr. Fernando Cura, Argentina. Dr. Samir Kapadia, Estados Unidos. This video, sponsored and funded by Medtronic, was filmed during SOLACI-CACI 2017 Congress, at Hilton Buenos Aires Hotel (in Argentina). Do you want to take a look at all other SOLACI-CACI 2017 Congress Medtronic cases? Watch them We are interested in your opinion. Please, leave...
TAVR: Cases of intermediate risk. Presenters: Dr. Oscar Méndiz, Argentina. Dr. Carlos Calderas, Venezuela. Dr. Anibal Damonte, Argentina. This video, sponsored and funded by Medtronic, was filmed during SOLACI-CACI 2017 Congress, at Hilton Buenos Aires Hotel (in Argentina). Do you want to take a look at all other SOLACI-CACI 2017 Congress Medtronic cases? Watch them We are interested in...
How to Avoid Patient Prosthesis Mismatch in TAVR. Presenters: Dr. Joel Estrada Gallegos, México. Dr. Gutierrez Jaikel, Costa Rica. Dr. Juan Gaspar, Uruguay. This video, sponsored and funded by Medtronic, was filmed during SOLACI-CACI 2017 Congress, at Hilton Buenos Aires Hotel (in Argentina). Do you want to take a look at all other SOLACI-CACI 2017 Congress Medtronic cases? Watch...